Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients

REGENXBIO Inc.4 enrolled

Overview

This study is designed to help identify patients with HoFH due to mutations in the LDLR as confirmed by genotyping.

This is a non-interventional study; no investigational product is administered in this study. Information collected in this study may be used to identify potential participants for clinical gene therapy trials in HoFH. The investigator will discuss the study with participants who have a clinical presentation consistent with HoFH and where possible, the treating physician, in order to assess their interest to participate. After informed consent has been obtained, participants will be asked to provide a blood sample (up to 40 mL) for genotyping to confirm genetic diagnosis of HoFH due to mutations in LDLR, a lipid panel and anti-AAV8 NAb titer. Participants and, whenever possible, their treating physician will complete a medical history questionnaire and provide supporting documentation. The informed consent form (ICF) and data collection methods may vary depending whether the informed consent is obtained remotely or at a participating study site. Information collected will include the following: * patient demographics (age, sex, weight) * medical history * previous genotype results (if available) * results of most recent lipid panel(s) * use of lipid lowering therapies, including failure to respond * assessment of presence of liver disease, including history of hepatitis B and C, human immunodeficiency virus (HIV), cirrhosis, and alcohol use Once this information is received by the investigator and Sponsor, a preliminary assessment of confirmation of a diagnosis of HoFH will be performed. Participants and/or their treating physician will be informed of the results of the genetic testing. All participants will be provided an opportunity to speak with a genetic counselor upon receiving the results of the genetic testing. Data collected in this study may be used to identify potential candidates for separate clinical trial(s) using gene therapy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Homozygous Familial Hypercholesterolemia (HoFH)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Males and females ≥ 18 years of age 2. Clinical presentation consistent with HoFH Exclusion Criteria: 1. History of cirrhosis based on documented histological evaluation or noninvasive imaging 2. Documented diagnosis of liver diseases 3. History of immunodeficiency diseases, including a positive HIV test result 4. Previous organ transplantation

Locations (1)

Excel Medical Clinical Trials, LLC

Boca Raton, Florida, United States

Outcomes

Primary Outcomes

The number of participants who have HoFH due to mutations in the LDLR gene measured by genetic testing

The number of participants who have HoFH due to mutations in the LDLR (low density lipoprotein receptor) gene as confirmed by genetic testing.

Time frame: baseline

Secondary Outcomes

The measurement of AAV8 NAb titers

The measurement of anti-AAV8 (adeno-associated virus serotype 8) neutralizing antibody (NAb) titers

Time frame: baseline

The measurement of LDL-C, total cholesterol, very low density lipoprotein cholesterol (VLDL-C), non-high density lipoprotein cholesterol (non-HDL-C), high density lipoprotein cholesterol (HDL-C), triglycerides (TG), and lipoprotein a (Lp[a])

Time frame: baseline

The number and types of the participant's current and historical lipid lowering therapies

The number and types of lipid lowering therapies, including LDL-C apheresis, the participant has been on or is currently on

Time frame: baseline

The participant's completion of the medical history questionnaire to determine relevant medical history

Collection of the participant's relevant medical history

Time frame: baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.